KSBB Journal

The Korean Society for Biotechnology and Bioengineering (한국생물공학회)
권호 표지

Effect of YGF251 on Secretion Of IGF-1 in Human Blood

YGF251 투여에 의한 인체내 혈중의 IGF-1 분비량 변화 효과

  • Published : 2002.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

For stimulating the in vivo secretion of IGF-1 (insulin-like growth factor-1) which is well known to promote the various physiological actions in human body, the natural herbal extract, YGF251 (young growth factor 251), was developed and evaluated for its effect as IGF-1 secretagogue in this study. The clinical study was peformed as double blind test, and 31 adult female and male volunteers between the age of 40 and 70 were investigated for their changes of concentration of IGF-1 , insulin level, weight, blood pressure, and liver and kidney functions. As the result of paired sample test on the change of the concentration of IGF-1, in YGF251 treated group, it was 245.6 ng/mL before dosing. The concentration of IGF-1 was increased to 269.3 ng/mL after a month and to 275.6 ng/mL after two months, and both were statistically significant (p〈0.05). While in control group, the concentration of IGF-1 was 280.0 ng/mL before dosing, but decreased to 239.2 ng/mL after a month and to 230.2 ng/mL after two months, and both were also statistically significant (p〈0.05). In YGF251 treated group, the concentration of insulin in blood increased about 2 times after a month dosing as an average level, but in control group, it showed a decrease of 36% compared with before dosing. And there were little changes regarding to the measured weight and blood pressure. Various measured data in order to observe the alteration in liver and kidney functions by the administration of YGF251 showed a little change within measuring error range.

인체의 다양한 기능을 증진시키는 작용을 하는 것으로 알려진 IGF-I의 생체내 분비를 촉진시키기 위해 천연 생약재성분으로 구성된 YGF251을 개발하였고 YGF251의 효능을 측정하였다. 이중 맹검 시험 방식으로 40세에서 70세 사이의 성인 남녀 31명을 대상으로 IGF-I을 비롯하여 체중, 혈압, 간기능 검사 및 신장기능 검사를 실시하였다. YGF251 및 위약 투석 후의 IGF-I 함량변화에 대한 대응표본 검정결과는 YGF251 투여군에서 투여 전에는 245.6 ng/mL 이었는데 1개월 투여 후에는 269.3 ng/mL, 2개월 투여 후에는 275.6 ng/mL으로 유의하게 증가하였다 (p<0.05). 한편 위약 투여군에서는 투여 전에는 280.0 ng/mL이었으나 1개월 투여 후에는 239.2 ng/mL, 2개월 투여 후에는 230.2 ng/mL으로 유의하게 감소하는 결과를 보였다(p<0.05). 혈중 insulin함량은 실험군의 경우 YGF251 을 1개월 투여후 평균치로써 2배 정도의 증가를 보였으며 위약 투여군에서는 36% 정도 감소된 것으로 나타났다. 또한 YGF251투여에 의한 체중 및 혈압의 변화는 거의 나타나지 않았다. YGF251 투여에 의해 나타날수 있는 간기능 및 신장기능 변화를 관찰 하기 위해 여러 항목들의 수치는 측정 오차 범위내에서의 변화만을 나타내었다.

Keywords

References

  1. Aizawa, H. (1998), Insulin-like growth factor-I, Brain and Nerve. 50(7), 606-613
  2. Le Roith, D. (1997), Seminars in medicine of the Beth Israel deaconess medical center. Insulin-like growth factors, N. Engl. J. Med. 336(9), 633-640 https://doi.org/10.1056/NEJM199702273360907
  3. Korsching, S. (1993), The neurothrophic factor concept: A reexamination, J. Neurosei. 13, 2739-2748
  4. Arsenijevic, Y., S. Weiss, B. Schneider, and P. Aebischer (2001), Insulin-like growth factor-1 is necessary for neural stem cell proliferation and demonstrates distinct aactions of epidennal growth factor and fibroblast growth factor-2, J. Neurosci. 21, 7194-7202
  5. Cappola, A. R., K. Bandeen-Roche, G. S. Wand, S. Volpato, and L. P. Fried (2001), Association of IGF-1 levels with muscle strength and mobility in older women, J. Clin. Endocrinol. Metab. 86, 4139-4146 https://doi.org/10.1210/jc.86.9.4139
  6. Shiotani, A., M. Fukumura, M. Maeda, X. Hau, M. Inoue, T. Kanamori, S. Komaba, K. Washizawa, S.Fujikawa, T. Yamamoto, C. Kadono, K. Watabe, H.Fukuda, K. Saito, Y. Sakai, Y. Nagai, J. Kanzaki, and M. Hasegawa (2001), Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector, Gene Ther. 8, 1043-1050 https://doi.org/10.1038/sj.gt.3301486
  7. Singleton, J. R. and E. L. Feldman (2001), Insulin-like growth factor-1 in muscle metabolism and myotherapies, Neurobiol. Dis. 8, 541-554 https://doi.org/10.1006/nbdi.2001.0416
  8. Thraikill, K. M. (2000), Insulin-like growth factor-1 in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility, Diabetes Technol. Ther. 2(1), 69-80 https://doi.org/10.1089/152091599316775
  9. Seck, T., C. Scheidt-Nave, G. Leidig-Bruckner, R. Ziegler, and J. Pfeilschifter (2001), Low serum concentrations of insulin-like growth factor 1 are associated with femoral bone loss in a population-based sample of postmenopausalwomen, Clin. Endoerinol. 55, 101-106 https://doi.org/10.1046/j.1365-2265.2001.01278.x
  10. Conti, E., F. Andreotti, A. Sciahbasi, P. Riccardi, G. Marra, E. Menini, G. Ghirlanda, and A. Maseri (2001), Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction, J. Am. Coli. Cardiol. 38, 26-32 https://doi.org/10.1016/S0735-1097(01)01367-5
  11. Nakao, Y., H. Otani, T. Yamamura, R. Hattori, M. Osako, and H. Imamura (2001), Insulin-like growth factor I prevents neuronal cell and paralegia in the rabbit model of spinal cord ischemia, J. Thorae. Cardiovasc. Surg. 122, 136-143 https://doi.org/10.1067/mtc.2001.114101
  12. Woods, K. A., C. CamachO-Hubner, R. N. Bergman, D. Barter, A. J. Clark, and M. O. Savage (2000), Effects of insulin-like growth factor 1 (IGF-1) therapy on body composition and insulin resistance in IGF-1 gene deletion, J. Clin.Endoerinol. Metab. 85, 1407-141 https://doi.org/10.1210/jc.85.4.1407
  13. Blum, W. F., K. Albertsson-Wikland, S. Rosberg, and M.B. Ranke (1993), Serum levels of insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 reflect spontaneous growth honnone secretion, J. Clin. Endoerinol. Metab. 76, 1610-1616 https://doi.org/10.1210/jc.76.6.1610
  14. Ranke, M. B., M. O. Savage, P. G. Chatelain, M. A. Preece, R. G. Rosenfeld, W. F. Blum, and P. Wilton (1995), Insulin-like growth factor I improves height ingrowth honnone insensitivity: two years' results, Horm. Res. 44, 253-264 https://doi.org/10.1159/000184637
  15. Huh, K. B., H. C. Lee, H. S. Kim, and J. H. Lee (1998), Influence of age on serum honnone levels, visceral fat area and thigh muscle mass in healthyKorean men, Kor. J. Intl. Med. 54(3), 406-414
  16. Kwon, S. J., Y. S. Jang, O. K. Kim, S. M. Lee, J. H. Lee, N. S. Chung, H. C. Lee, and K. B. Huh (1999), Influence of age and obesity on visceral fat, muscle mass and cardiovascular risk actors in healthy Korean men, Kor. J. Lipidol. 9(4), 393-405
  17. Dore, S., S. Kar, and R. Quirion (1997), Rediscovering an old friend, IGF-1: potential use in the treatment of neurodegenerative disease, TINS, 20, 326-331
  18. Laron, Z. (1993), Somatomedin-1 (Insulin-like growth factor-1) in clinical use, Drugs, 45(1), 1-8 https://doi.org/10.2165/00003495-199345010-00001
  19. Chevalley, T., R. Rizzoli, D. Manen, J. Caverzasio, and J. P. Bonjour (1998), Arginine increase insulin-like growth factor-1 production and collagen synthesis in osteoblast-like cells, Bone, 23(2), 103-109 https://doi.org/10.1016/S8756-3282(98)00081-7
  20. Wideman, L., J. Y. Weltman, J. T. Patrie, C. Y. Bowers, N. Shah, S. Story, A. Weltman, and J. D. Veldhuis .(2000), Synergy of L-arginine and growth honnone(GH)-relaeasing peptide-2 on GH release: influence of gender, Am. J. Physiol. Regul. Integr. Camp. Physiol. 279(4), R1455-l466